Y. Aoki

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

K. Maeda, H. Kusuhara, X. Chu, 2022, Clinical and translational science.

Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data

B. Scirica, J. Nyström, I. Raz, 2022, PloS one.

Revisiting nonlinear bosentan pharmacokinetics by PBPK modeling: Target binding, albeit not a major contributor to nonlinearity, can offer prediction of target occupancy

Wooin Lee, K. Toshimoto, S. Koyama, 2021 .

Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase

G. N. Norén, H. Taavola, Lovisa Sandberg, 2020, Drug Safety.

Cluster Gauss–Newton method

K. Hayami, K. Toshimoto, Yuichi Sugiyama, 2020, Optimization and Engineering.

Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs

P. Gennemark, Alessandro Boianelli, A. Dahlén, 2022, Nucleic acid therapeutics.

Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models

A. Hooker, R. Bauer, Y. Aoki, 2020, The AAPS Journal.